Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical…
1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
1cBio has struck a regional licensing deal with Hong Kong-based Lee’s Pharmaceutical Holdings to advance OC-3, its next-generation selective PARP1 inhibitor, across Greater China and parts of Southeast Asia. Under the agreement announced September 9,…
CTTQ’s HER2 Bispecific ADC TQB2102 Hits Phase 3 Endpoints in HER2-Low Breast Cancer, Setting Up China Filing
Chia Tai Tianqing Pharmaceutical Group (CTTQ), a core subsidiary of Sino Biopharmaceutical, has reported a major late-stage clinical win for TQB2102 (rolditamig deuderuxtecan), its internally developed HER2 bispecific antibody-drug conjugate (ADC). The…
Akeso’s Ivonescimab Outshines Pembrolizumab on Overall Survival in Phase 3 HARMONi-2 Trial
China’s Akeso has reported another major clinical milestone for ivonescimab (AK112), its first-in-class PD-1/VEGF bispecific antibody, announcing that the drug demonstrated a statistically significant and clinically meaningful overall survival (OS)…
HUTCHMED Licenses KRAS-EGFR ATTC HMPL-A830 to GSK in Deal Worth Up to $1.295 Billion
China-based biopharmaceutical company HUTCHMED has entered into an exclusive global licensing and development agreement with GSK for HMPL-A830, a potentially first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), in a transaction that could…
Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
Simnova Raises Nearly RMB 400 Million in Series B Financing to Advance CAR-NK and In Vivo CAR-T Platforms
Shanghai-based cell therapy developer Simnova has completed a nearly RMB 400 million (approximately US$55 million) Series B financing round, providing fresh capital to advance its lead off-the-shelf CAR-NK program SNC103 and its emerging in vivo CAR-T…
Chia Tai Tianqing Pharma (CTTQ)
Innovating for Life, Creating Greater Health Value
CStone Pharmaceuticals
Building Globally Competitive Innovative Medicines